Skip to main content
. 2021 Jun 8;13(12):2865. doi: 10.3390/cancers13122865

Figure 1.

Figure 1

Study overview. High quality reagents including recombinant C9, C9 antibody and serum purified C9 were generated and used to develop C9 ELISA and EndoScreen Chip. The newly established assays were evaluated in a case-control cohort. Logistic regression was used to develop diagnostic algorithms for predicting BE or EAC, by combining blood markers with risk factors.